Observational study shows 62% uptake of nirsevimab in immunocompromised children, suggesting improved strategies needed for RSV protection.
Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long-acting monoclonal antibody approved in 2023, offers single-dose seasonal protection. We conducted a single-center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024-2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non-recipients, including one RSV-related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: